NeuroPace

Join us at AAN 2025 for a must-see presentation: Results of the RNS System Post-Approval Study for Drug-Resistant Focal Epilepsy The 3-year results of the RNS? System Post-Approval Study are in—offering new insights into brain-responsive neuromodulation for drug-resistant focal epilepsy. ? How have outcomes improved compared to earlier studies? ? What does this mean for the future of epilepsy treatment? ??Tuesday, April 8 | 12:00 PM PT ?? AAN Exhibit Hall Presentation Stage Learn more: https://lnkd.in/gAeku8qv Important Safety Info: www.neuropace.com/safety

Wearing purple today? ?? NeuroPace proudly supports Purple Day #EpilepsyAwareness! Learn about Purple Day for Epilepsy: https://lnkd.in/g5FUXMBY

Today is Purple Day! ?? We invite people everywhere to wear purple to support epilepsy awareness! Learn about Purple Day for Epilepsy: https://lnkd.in/g5FUXMBY #EpilepsyAwareness #PurpleDay

Can’t Attend AAN 2025? We’ve Got You Covered. Join Dr. Dawn Eliashiv & Dr. Martha Morrell for an exclusive live webinar as they break down the 3-year Post-Approval Study data on the RNS? System. ?? Tuesday, April 8 | 8:00 AM PT ?? Friday, April 11 | 12:00 PM PT See why the results reinforce the RNS System as a first-line option in neuromodulation. Register here: https://lnkd.in/g2rqTQpA Important Safety Info: www.neuropace.com/safety

Purple Day is an international grassroots effort dedicated to increasing awareness about epilepsy worldwide. ???? Learn about #PurpleDay for Epilepsy: https://lnkd.in/g5FUXMBY #EpilepsyAwareness

Join leading experts as they present the latest 3-year results from the RNS? System Post-Approval Study—offering key insights into neuromodulation for drug-resistant focal epilepsy. AAN 2025 Event Lineup: Multicenter Post-approval Study of the RNS System in Focal Epilepsy – Dawn Eliashiv, MD ?? Monday, April 7 | 5:06 PM PT | ?? San Diego Convention Center | 29A Unmatched Outcomes: ?Results of the RNS System Post-approval Study for Drug Resistant Focal Epilepsy – Martha Morrell, MD & Barbara C. Jobst, MD ?? Tuesday, April 8 | 12:00 PM PT | ?? AAN Exhibit Hall Presentation Stage Learn more at https://lnkd.in/gAeku8qv Important Safety Info: www.neuropace.com/safety

The 3-year results of the RNS? System Post-Approval Study are here. Dr. Dawn Eliashiv — renowned epileptologist, researcher, and leader in the field — will present the long-term data on brain-responsive neuromodulation and what it means for patients with drug-resistant focal epilepsy. ?? Monday, April 7 | 5:06 PM PT ?? San Diego Convention Center | 29A This is data-driven insight from a leading expert—don’t miss it. Learn more: https://lnkd.in/gAeku8qv Important Safety Info: www.neuropace.com/safety

How does the RNS? System compare in long-term seizure reduction? The 3-year results from the RNS System Post-Approval Study have the answer. ?? Monday, April 7 | 5:06 PM PT ?? San Diego Convention Center I 29A Be among the first to see the data from the largest FDA-reviewed prospective study in neuromodulation for focal drug-resistant epilepsy. ?? Learn more: https://lnkd.in/gAeku8qv Important Safety Info: www.neuropace.com/safety

??Congratulations to Dr. Erik Larson and Dr. Cliff Hampton at Kootenai Health on completing the first RNS System case in Idaho, bringing new hope to patients with drug-resistant #epilepsy. This young woman has battled seizures since childhood, experiencing daily episodes that impacted her safety, independence, and ability to work. After trying multiple medications without success, she now has the RNS System—a breakthrough in responsive neurostimulation designed to help reduce #seizures in real time. With leaders like Dr. Larson pushing the boundaries of epilepsy care, more patients have the opportunity to regain control of their lives. RNS Safety Info: www.neuropace.com/safety

We're #hiring a new Downstream Senior Marketing Manager in Mountain View, California. Apply today or share this post with your network.